Background and context
Who wrote it
Bailey is at Aston University in Birmingham. Flatt and Conlon are at the Diabetes Research Centre at Ulster University in Coleraine, Northern Ireland. PubMed lists no company affiliation for any of the three. It does not show funding or competing-interest statements, which we have not checked in the full paper.
The design history it traces
The abstract starts with pramlintide, the first useful amylin receptor agonist, which was based on the structure of rat amylin because that form does not aggregate. It says a better picture of the amylin and calcitonin receptor complex helped in designing a second generation of non-aggregating, long-acting analogues, and it places eloralintide among the recently developed ones.
How much of the review is about eloralintide
Not much. The review also covers cagrilintide, CagriSema, amycretin, petrelintide, Met-233 and AZD6234, so eloralintide is one entry in a wider survey of the class.
Bailey CJ, Flatt PR, Conlon JM, Peptides, 2026, volume 196, article 171480, via PubMed (PMID 41747885). DOI 10.1016/j.peptides.2026.171480.